January 24, 2014
Teva Pharmaceuticals Inc. and Boehringer Ingelheim Pharmaceuticals Inc. were slapped on Friday with another proposed class action, this one in Pennsylvania federal court, over an alleged $120 million deal to delay the entry into the market of a generic version of a stroke-prevention medication.